Biocon hopes sales of biosimilars will triple

In a chat with ET Now, Mitesh Thacker, Technical Analyst, miteshthacker.com, gives his overview on Biocon. ET Now: What is your call on Biocon? Mitesh Thacker: Biocon is a 'SELL' call with a target of Rs 265 and a stop loss of Rs 280.5. Follow Economic Times ...

The new drug policy is unfavourable to big players feels Kiran Mazumdar Shaw, but adds that Biocon will not be impacted significantly by it.

Follow Economic Times Views/Recommendations Section, For The Latest News! EmailRSS Have something to say? Post your comment Comments are moderated and will be allowed if they are about the topic and not abusive. Characters remaining ( 1500 ) To post this ...

Bilcare, India's leading innovation-driven technology solution company has been associated with Biocon, country's largest biopharma company, to provide secure, non-clonable 'Track & Trace technology' for protection of Biocon's exports across globe. Tweet -- ...

Biotechnology giant Biocon on Friday reported an impressive jump of more than two-fold in its consolidated net profit for the quarter through March 31, thanks to a steep jump in exceptional income. Biocon announced that its consolidated net profit ...

"The biggest problem is that investors do not want us to spend on R&D and R&D is a very integral part of our business."

Biocon has dipped 4% to Rs 278 after reporting 21% year-on-year (yoy) drop in its consolidated operating profit at Rs 124 crore for the quarter ended March 2013 (Q4) due to higher material, power and staff cost.

Pharma stocks like Cipla, Aurobindo Pharma, Lupin, Sun Pharma and Biocon will be geting astological support, says Satish Gupta of Astrostocktips.

Biotechnology major Biocon plans to launch in July its novel biologic drug Itolizumab branded as Alzumab to be used for the treatment of chronic plaque psoriasis in the country.We pla...